Lawrence Morton, MD
Disclosures: ,Speakers Bureau-Greenwich Bioscience
Curriculum Vitae

Curriculum Vitae

Lawrence D. Morton, M.D.

Page 1 

CURRICULUM VITAE

LAWRENCE DANIEL MORTON, M.D.

 

 

  1. Personal Information

 

1.1                          Lawrence Daniel Morton

1.2                          Home:              13439 Glendower Road, Midlothian, VA  23113

1.3                          Office:              Virginia Commonwealth University

Department of Neurology

Division of Child Neurology

PO Box 980211 

Richmond, VA  23298-0211 

Phone:              804-828-0442

 

  1. Licensure

 

Virginia, 0101051122

Pennsylvania, 042485-L – inactive

ABPN, Neurodevelopmental Disabilities, Board Certified, 2004

ABPN, Clinical Neurophysiology, Board Certified April 1997

ABPN, Clinical Neurophysiology, Recertification, 2016

ABPN, With Special Expertise in Child Neurology, Board Certified, 1997

ABPN, With Special Expertise in Child Neurology, Recertification, 2016

American Board of Pediatrics, Board Certified, 1991

American Board of Pediatrics, Recertification, 1998

National Board of Medical Examiners, Diplomat, 1989

 

  1. Education

06/1988              M.D., SUNY Health Science Center, Brooklyn, NY

06/1984              B.S., Engineering, Manhattan College, Bronx, NY

 

  1. Military Service Record – N/A

 

5.   Postdoctoral Training or Special Experience

 

07/1994-06/1995              Fellowship training, Clinical Neurophysiology, Virginia                                                                                     Commonwealth University

07/1991-06/1994              Resident, Child Neurology, Hospital of the University of                                                                            Pennsylvania/Children’s Hospital of Philadelphia

07/1989-06/1991              Resident, Pediatrics, St. Christopher’s Hospital for Children, Philadelphia, PA

07/1988-06/1989              Intern, Pediatrics, St. Christopher’s Hospital for Children,              

Philadelphia, PA


  1. Academic Appointments or Other Significant Work Experience

 

12/2017 – present               Co-Director Tuberous Sclerosis Program

5/2016-present               John M “Jack” Pellock Professor of Neurology

1/14-present              Chair, Division of Child Neurology, Virginia Commonwealth University

7/08-present              Professor, Neurology and Pediatrics, Virginia Commonwealth University Medical Center

7/06-present                            Director, Clinical Neurophysiology Fellowship

7/04-6/08              Associate Professor, Neurology and Pediatrics, Virginia Commonwealth University Medical Center

8/01-present              Director, Division of Clinical Neurophysiology Laboratories, Department of Neurology, Virginia Commonwealth University Medical Center             

              3/01-08/01                            Associate Director, Clinical Neurophysiology, Virginia                                                                                     Commonwealth University Medical Center

1997-2001              Associate Director, Epilepsy Monitoring Unit for Pediatric Patients, Virginia Commonwealth University Health Systems

1996-2001              Director, Pediatric EEG, Virginia Commonwealth University Health Systems

1994-7/04              Assistant Professor, Neurology and Pediatrics, Virginia Commonwealth University Health Systems

              1993-1994                            Course Instructor, Neurology, University of Pennsylvania

              1992-1993                            Assistant Course Instructor, Neurology, University of                                                                                     Pennsylvania

 

  1. Membership – Scientific, Honorary and Professional Societies

 

              1999                            Medical Society of Virginia

              1995                            American Epilepsy Society

              1993                            Child Neurology Society

              1992                            American Academy of Neurology

              1988                            American Academy of Pediatrics, Fellow

 

  1. Membership in Community Organizations

 

1988                   Knights of Columbus

 

  1. Special Awards, Fellowships and Other Honors

 

9.1 Awards

1983       Pen and Sword Society, Manhattan College

1987       Alpha Omega Alpha Honor Society

9.2 Fellowships

1993              Mini-Fellowship, Bowman Gray Course in Epilepsy

9.3 Child Neurology Outstanding Teacher Award, Virginia Commonwealth University, 2012 and 2015

 

9.4 External Grants

 

Principal Investigator: (GWEP1415) An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet or Lennox-Gastaut Syndromes 8/2016-present

 

Principal Investigator: GWEP1423 A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Cannabidiol as Adjunctive Treatment for Seizures Associated with Lennox-Gastaut Syndrome in Children and Adults.  Protocol GWEP42003-P: CBD06/15 – 10/2016.

 

Principal Investigator: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial of STUDY DRUG as an Adjunct Therapy in Dravet Syndrome.  Protocol GWEP1424.  06/15 – present.

 

Sub-Investigator:  Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE).  09/2014-07/2015

 

Sub-Investigator:  A Randomized, Double Blind, Placebo-Controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects with Seizure Clusters.  ARTEMIS-1 Acute Rescue Therapy in Epilepsy with Midazolam Intranasal Spray -1.  Protocol P261-401.  05/2014-05/2017

 

Sub-Investigator:  A 12-Month Open-Label Study to Evaluate the Safety and Tolerability of Pregabalin as Adjunctive Therapy in Pediatric Subjects 1 Month to 16 Years of Age with Partial Onset Seizures and Pediatric and Adult Subjects 5 to 65 Years of Age with Primary Generalized Tonic-Clonic Seizures. A0081106-1109.  02/2012-12/2016

 

Principal Investigator:  A Phase 3, Randomized, Double-Blind, Parallel, Placebo-Controlled, Multicenter Study with Optional Open-Label Continuation of the Efficacy and Safety of VanquixTM  Auto-Injector (Diazepam Injection) for the Management of Selected Refractory Patients with Epilepsy who Require Intermittent Medical Intervention to Control Episodes of Acute Repetitive Seizures.  Protocol K826-05-3001, 11/09-07/14.

 

Sub-Investigator:  A 14-Month Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures.  Protocol E2007-G000-307, 10/2008 – 01/2013.

 

 

Sub-investigator:  A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures.  Protocol E2007-G000-304, 10/2008-8/2011.

 

Principal Investigator:  Open Label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children with Epilepsy.  Protocol N01275, 09/2008 – 8/2010.

 

Sub-Investigator:  An Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures.  Protocol E2080-A001-302, 9/07 – 9/2010.

 

Sub-investigator:  Double-Blind, Placebo Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome.  Protocol OV-1012, 09/07 – 12/2010.

 

Sub-investigator:  A Double-Blind, Placebo-Controlled, Dose-Ranging Clinical Study to Evaluate the Safety, Tolerability, and Antiepileptic Activity of Ganaxolone in Treatment of Patients with Infantile Spasms.  Protocol 1042-0500, 3/07 – 11/08.

 

Sub-investigator:  An Open-Label Clinical Study to Evaluate the Safety and Antiepileptic Activity of Ganaxolone in Treatment of Patients Diagnosed with Infantile Spasms.  Protocol 1042-0501, 3/07 – 11/2009.

 

Sub-investigator:  A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures.  E2080-A00-301, 01/07- 9/2010.

 

Sub-investigator:  The Safety and Effectiveness of Open-Label Clobazam in Subjects with Lennox-Gastaut Syndrome.  Protocol OV-1004, 08/05–1/2012.

 

Sub-investigator:  The Safety and Efficacy of Clobazam in Subjects with Lennox-Gastaut Syndrome.  Protocol OV-1002, 08/05 – 11/06.

 

Sub-investigator:  An Open-Label Multicenter Study of the Long-Term Safety of Depakote Sprinkle Capsules in the Treatment of Partial Seizures in Children.  Protocol M04-714, 05/05- 12/07.

 

Sub-investigator:  An Open-Label Extension Trial to Determine the Safety and Efficacy of Long-Term Oral SPM 927 In Patients With Partial Seizures.  Trial Number SP756, 09/04 – 9/2010.

 

Sub-investigator:  A Multi-Center, Open-Label, Long-Term, Follow-Up Study of the Safety and Efficacy of Levetiracetam in Children with Partial Onset Seizures.  Protocol No. N01148, 08/04- 6/08.

 

Principal Investigator:  A Double-Blind, Randomized, Multi-Center, Placebo-Controlled, In-Patient, Maximum 24 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Ranging in Age From 1 Month to Less Than 4 Years of Age.)  Protocol No. 1009, 05/04-12/06.

 

Sub-investigator:  A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to Investigate the Efficacy and Safety of SPM927 (400 and 600mg/Day) As Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization.  Protocol No. SP754, 02/04-11/06.

 

Sub-investigator:  A 19 week, Randomized, Double-Blind, Multi-center, Placebo-Controlled Safety Study to Evaluate the Cognitive, and Neuropsychological Effects of Levetiracetam 20-60 mg/kg/day.  Divided in Twice Daily Dosing, as Adjunctive Treatment In Children 6-16 Years Old, Inclusive With Refractory Partial Onset Seizures.  Protocol No. N01103, 01/04-12/06.

 

Principal Investigator: A Comparison of the Efficacy and Safety of Topiramate Versus Placebo for the Prophylaxis of Migraine in Pediatric Subjects (Protocol CAPSS-122), 06/02.

 

Principal Investigator: Open-Label, Long-Term Safety Study of Zonisamide (ZonegranTM) Administered to Children with Epilepsy. Protocol No. AN46046-354, 02/01

 

Principal Investigator: A Multicenter, Open Label, Safety Study to Evaluate the Use of 25 mg and 50 mg ZonegranTM (zonisamide) in the Initiation of Therapy in Patients with Epilepsy. Protocol Number ZNS-501, 10/00-10/01

 

Sub-investigator: A Multicenter, Open Label, Safety and Efficacy Study of Zonegran TM in Patients with Progressive Myoclonic Epilepsy ZNS-502 Elan Pharma 09/00-05/01

 

Sub-investigator: A Multicenter, Open Label, Long-Term, Follow-Up Study of the Safety and Efficacy of Levetiracetam (UCB L059) in Children with Epilepsy.  Protocol No. RPCE97L260, UCB Pharma Inc. 08/00

 

Investigator: P50NS25630 (DeLorenzo) NIH/NINDS.  Medical College of Virginia Epilepsy Research Center.  To develop a prospective, population data base for status

epilepticus and to evaluate predictive indicators of outcome and epidemiological and clinical parameters.  2/1/00-1/31/11.

 

Principal Investigator: Tiagabine and Treatment of Infantile Spasms (A Pilot Study), 03/00

 

Sub-investigator: Evaluation of the Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients with Partial Onset Seizures: A 28 Week Double-Blind, Placebo-Controlled Multicenter Trial, Protocol RPCE98B2502, UCB Pharma Inc., 08/99

 

Sub-investigator: Open-Label, Safety Study of Gabapentin (CI-945) as Adjunct Therapy in Children Aged 1 Month Through 4 Years with Seizures Uncontrolled by Current Anticonvulsant Drugs (Protocol 945-301) 03/99

 

Investigator: Multicenter, Double-Blind, Randomized, Placebo-Control, Parallel-Group, Monotherapy Study of Rufinamide in Inpatients with Refractory Partial Seizures Who Have Completed an Evaluation for Epilepsy Surgery, CRUF331 0038, Novartis Pharmaceuticals Corporation, 1999-present

 

Sub-investigator: Open-label Dose Titration Assessment of the Clinical Utility of a Slow, Low Dose Titration Schedule of ZonegranTM (zonisamide) in the Initiation of Therapy in Patients with Partial Seizures, Protocol ZNS-401, Elan Pharma 01/99-01/01

 

Children’s Miracle Network Grant – Evaluation of Infant Apnea: $10,000, 1999

 

Sub-investigator: A Long-term Open Label Safety Study of Remacemide Hydrochloride in Subjects with Epilepsy, Smith-Kline Beecham, 09/98

 

Sub-investigator: An Inpatient, Double-Blind, Placebo-controlled, Parallel Group Study of Remacimide Hydrochloride as Monotherapy in Subjects with Partial-onset Seizures, Smith-Kline Beecham, 05/98

 

Principal Investigator: A Pharmacokinetic Study to Evaluate CL-1008 Absorption after Administration of an Oral Dose (by intubation) to Healthy Volunteers, Protocol 1008-004, CDS#6PD01, 11/96

 

Principal Investigator: In Vitro Plasma Protein Binding of Fosphenytoin, Phenytoin, and Fosphenytoin-phenytoin in Combination in Human Neonatal Blood (Protocol 9609-3B), Parke Davis, 09/96

 

Principal Investigator: An Open-Label, Safety, Tolerance, and Pharmacokinetic Study of Intravenous and Intramuscular Fosphenytoin (Cerebyx) in Children Less Than 16 Years of Age (Protocol 982-028), Parke-Davis, 04/96

 

Principal Investigator, Ex Vivo Study of Fosphenytoin (CJ-982) Conversion in Neonate Blood, Parke-Davis, 04/96

 

Co-Investigator: Long-Term Safety Follow-up for Selected Patients who Previously participated in Vigabatrin Trials (Protocol 071754PRO253), 01/96

 

Medical Investigator: Absorption of Rectal Diazepam from a Foam Dosage Form, CDS#6SC01, Schiarra Labs, 02/97.

 

Medical Investigator: The Absorption of Methylphenidate Administered in Solution by Intubation to the Proximal and Distal Colon in Healthy Subjects, CDS# 7Alo1, Alza Corporation Study No. C-97-024-00, 09/97

 

Medical Investigator: Rising, Single-Dose, Safety, Tolerability, and Pharmacokinetics of GumsmokeTM Tobacco Chewing Gum in Healthy Volunteer Smokers, CDS#7ST01, Star Tobacco & Pharmaceuticals, Inc., 09/97

 

Sub-investigator: Changes in Clearance of Antiepileptic Drugs During Puberty, NO.NIH-NINDS-96-05, 10/96

 

Sub-investigator: An Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Ganaxolone as an Add-On Therapy in Patients with Refractory Seizures and a History of Infantile Spasms (Protocol 1042-0101.01), 04/96.

 

Subinvestigator: A Double-Blind Trial of Topiramate in Subjects with Lennox-Gastaut Syndrome (Protocol YL), 09/95

 

Sub-investigator: Remacimide Inpatient Seizure Evaluation Trial – CR 2268 (ACV-201, 07/95

 

Sub-investigator: Dose-Response Study of Efficacy and Safety of Vigabatrin (Sabril ®) Therapy Compared to Placebo in Children with Uncontrolled Complex Partial Seizures: a Dose Response Study (Protocol 071754PRO0242)

 

Sub-investigator: Safety and Efficacy of Tiagabine HCL as Adjunctive Treatment (Protocol M92-825), 02/95

 

Sub-investigator: An Open-Label, Follow-Up, Long-Term Maintenance Study of Vigabatrin (Sabril®) as Monotherapy in Children with Complex Partial Seizures (Protocol 071754PRO201)

 

Sub-investigator: A Multicenter, Randomized, Double-Blind Placebo-Controlled Parallel, Add-On Trial of Oxcarbazepine Tablets in Children with Inadequately Controlled Partial-Onset Seizures (Protocol 47680-02-011), 02/95

 

Sub-investigator: A Long-Term Follow-up Open Study of Remacimide Hydrochloride for Safety and Tolerability in Patients with Medically Refractory Epilepsy-CR 2427 (ACV-201C)

 

Sub-investigator: A Follow up Open Study of Remacimide for Safety and Tolerability in Patients with medical Refractory Epilepsy -CR2269 (ACV-201B), 07/95

 

Sub-investigator: Protocol 123, IND#43,551.  Lamotrigine as Add-on Therapy in Patients with a Clinical Diagnosis of a Lennox-Gastaut Syndrome (Severe Generalized Epilepsy of Childhood Onset).  A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study.  Burroughs Wellcome, started 12/94

 

Sub-investigator: A Double-Blind Parallel Group Comparison of Gabapentin vs. Placebo as Add-On Therapy for Epilepsy in Children (Protocol #945-186). Parke Davis, started 11/94

 

Sub-investigator: An Open-Label Extension Study of Gabapentin in Children with Epilepsy who have Participated in the Double-Blind Study (Protocol #945-187). Parke Davis, started 11/94.

 

Sub-investigator: A Multicenter, Double-Blind, Active-Control evaluation of the Efficacy and Safety of Lamotrigine Monotherapy in Patients with Partial Seizures (Protocol 30), 07/94.

 

9.5 Invited Seminars

 

21st Annual Pediatric Epilepsy Symposium, “Hot Topics in Pediatric Epilepsy”, Wake Forest University, Ashville, NC 02/23/2018

 

Hans Berger Clinical Neurophysiology Symposium, “EEG Monitoring and Therapeutic Hypothermia”, VCU, Richmond, VA 05/18/2015

 

Hans Berger Clinical Neurophysiology Symposium, “FIRES (Febrile Infection Related Epilepsy Syndrome): A Case Based Discussion, VCU, Richmond, VA 05/20/2013

 

Grand Rounds, “Treatment of Seizures in the Multiply Handicapped”, VCU, Richmond, VA 12/20/2012.

 

Hans Berger Clinical Neurophysiology Symposium, “Case Discussions: Post Traumatic Seizures”, VCU, Richmond, VA 05/21/2012.

 

Hans Berger Clinical Neurophysiology Symposium, “Update on Infantile Spasms”, VCU, Richmond, VA 05/23/2011.

 

Hans Berger Clinical Neurophysiology Symposium, “How Have Advances in Neurophysiological Testing Impacted Epilepsy Care”, VCU, Richmond, VA 05/24/2010.

 

Hans Berger Clinical neurophysiology Symposium, “Is This Patient a Surgical Candidate? VCU, Richmond, VA 05/18/2009.

 

Grand Rounds, “Pediatric Epilepsy Surgery”, VCU, Richmond, VA, Department of Pediatrics, 01/08/2009.

 

Hans Berger Clinical Neurophysiology Symposium, “Rasmussen’s Encephalitis:  An Update”, Richmond, VA, 5/20/2008

 

Messina/VCU Neuroscience Course, “Workup for Epilepsy Surgery-Peds/Adults”.  VCU, Richmond, VA, 6/21/07

 

Hans Berger Clinical Neurophysiology Symposium, “Epilepsy Monitoring-Pediatric Cases”, Richmond, VA, 5/21/07

 

The 28TH Annual Pediatric Primary Care Conference, “Status Epilepticus 2006 Guidelines”, VCU, Richmond, VA, 07/14/06

 

Messina/VCU Neuroscience Course, “Workup for Epilepsy Surgery-Peds/Adults”.  VCU, Richmond, VA, 6/13/06

 

AADMD symposium, “Maximizing Benefits from new AEDs in the Developmentally Disabled”, Southern Illinois University School of Medicine, teleconference, 04/21/06

 

Grand Rounds, “Epilepsy Surgery in Pediatric Patients”, VCU, Richmond, VA, Department of Pediatrics, 04/01/03

 

Grand Rounds, “Epilepsy Surgery in Pediatric Patients”, University of South Alabama, Mobile, AL 07/11/01

 

Hans Berger Clinical Neurophysiology Symposium “Problem Epilepsies of Late Childhood”, Richmond, VA 05/21/01

 

Hans Berger Clinical Neurophysiology Symposium “Treatment of Post Traumatic Seizures”, Richmond, VA 05/22/01

 

Roundtable: “Challenges in the Management of Seizure Disorders in Pediatric Patients”, Sponsored through Johns Hopkins University, Aspen, CO, 01/26-27/01

 

Epilepsy Educators Conference: “Pitfalls in the Diagnosis of Pediatric Epilepsy”, Sponsored by Ortho-McNeil, New Orleans, LA, 11/03/00

 

Hans Berger Clinical Neurophysiology Symposium, “Pitfalls in the Diagnosis of Pediatric Epilepsy”, Richmond, VA 05/23/00

 

Hans Berger Clinical Neurophysiology Symposium, “Pediatric Epilepsies and Sleep”, Richmond, VA 05/16/99

 

Grand Rounds: “New AEDs in Children”, Department of Neurology, University of Alabama, Birmingham, AL, 03/22/99

 

Grand Rounds:  “Sleep Disorders in Neurologic Conditions”, VCU, Richmond, VA, Department of Pediatrics, 02/09/99

 

Grand Rounds:  “Neonatal Seizures”, University of Virginia Medical Center, Charlottesville, VA, 11/06/98

 

Hans Berger Clinical Neurophysiology Symposium “Evaluation of Coma in the Neonate”, Richmond, VA 05/18/98

 

Hans Berger Clinical Neurophysiology Symposium “Neonatal Status Epilepticus”, Richmond, VA 05/19/98

 

Roundtable: “Management of Acute Seizures in Children” Sponsored by Virginia Commonwealth University, Boston, MA 12/05/97

 

Grand Rounds: “Acute Repetitive Seizures”, Virginia Commonwealth University, Sponsored by Elan Pharma 09/25/97

 

Presenter, Platform Session: “CSF Findings in Status Epilepticus”, American Epilepsy Society, San Francisco, 12/96

 

Grand Rounds: “Status Epilepticus: Update”, Walter Reed Medical Center, Sponsored by Abbott 11/13/96

 

Hans Berger Clinical Neurophysiology Symposium “Neonatal Neurophysiologic Techniques”, Richmond, VA 05/19/96

 

Hans Berger Clinical Neurophysiology Symposium “Early Childhood Epilepsy”, Richmond, VA 05/21/96

 

10.              Major Committees

 

10.1         University

2017-18              Neurology Chairman Search Committee

2017-18              Chair, Promotion Committee, Syndi Seinfeld

2017-18              Chair, Promotion Committee, Soundarya Gowda

2017-18              Member, Promotion Committee, Wei Zhoa

2016-18              Pediatric Neuro-oncology Chair Committee

2014-16              Neurosurgery Chair Search Committee

2008-09                   Neurology Chairman Search Committee

2009                            Safety First Physician Leadership Retreat

5/07-present              AGME Internal Review Committee, Chair

06/06-01/08              Children’s Hospital Planning Committee

03/0603/08              CCH Tower Planning Committee

              2000-01              Neurology Chairman Search Committee

              2000-06              Annual Hans Berger Day Clinical Symposium Organizing                                                         Committee

              1995-present              Resident Selection Committee, VCUHS

              1995-present              EMU Clinical Committee, VCUHS

10.2              Professional

              N/A

 

11.              Other Significant Scholarly, Research or Administrative Experience

 

11.1              Graduate Students Trained

 

2001-2002              B. Patrick Coots, PharmD

Maria Ibrahim, PharmD

                            J. T. Graham, PharmD

 

11.2              Postdoctoral Trainees

 

2017-present Ewa M Way, M.D.

 

2016-2017              Robert Baldwin, M.D.

 

2015-2016               Fermina Pirmohamed, MD

 

2014-2015              Kenichiro Ono, D.O.

                            Thuy Ahn Vu, M.D.

 

2013-2014               Binod Wagle, M.D.

 

2012-2013               Diane Hesselbrock, M.D.

Julio Ventura, M.D.

 

2011-2012              Carrie Ham, M.D.

                            Kamran Kabolizadeh M.D.

                            Syndi Seinfeld, D.O.

 

2010-2011              Soundarya Gowda, M.D.

                            Chike Linton, M.D.

                            Sheetal Wagle, M.D.

 

2008-2009              Jo-Hsin Chen, D.O.

                            Ajo Joy, M.D.

 

2007-2008              Sejal Jain, M.D.

                            Grace Mukamana, M.D.

                           

2006-2007              Elsa Varughese, M.D.

                            Leslee Hudgins, D.O.

                           

2005-2006              Scott Vota, D.O.

                            Syed Salahuddin, M.D.

                            Vera Korol, M.D.

 

2004-2005              Venkata Jakkampudi, M.D.

 

2003-2004              Patricia Eller, M.D.

                            Reena Thomas, M.D.

 

2002-2003              Mehmet Gulhan, M.D.

 

2001-2002              Waleed Nazmy, MD

                            Lenore Joseph, MD

                            Rajiv Nanavaty, MD

 

2000-2001              Herman Gatuslao, MD                           

Lydia Kernitsky, MD                           

David Leszczyszyn, MD

                            Yamini Yarlagadda, MD

                            Pierre Pavot, MD

 

1999-2000              S. Chodisetty, MD

                            Miriam Garcia, MD

                            Muhammad Rahman, MD

                            Olavo Vasconcelos, MD

                            Carl Waldman, MD

 

1997-1998              Sarbjot S. Dulai, MD

                            John J. Lucas, IV, MD

                            Anthony Quan Hong, MD             

                            Joseph K. Vaughan, MD

 

1996-1997              Daniel Garber, MD

                            Nathan Watemberg, MD             

 

1995-1996              Mourad Adelmessih, MD

                            Naomi Mann, MD

 

11.3              Major Teaching Assignments

 

1994-1999              Neonatal EEG review system, Thursday’s AM, Virginia                                                                       Commonwealth University, Richmond, VA

              1994-present              Neurology Wards and Consult Services, daily teaching                                                         of housestaff, medical students

              1994-present              MIII, Seizure clinic preceptor

              1995-present              Clinical Neurophysiology Course Faculty, Virginia             

1995-present              EEG Laboratory/Epilepsy Monitoring Unit Teaching of Clinical                                           Neurophysiology fellows, residents, students

1999-2008              MII, Course Faculty, Pulmonary Course, Virginia Commonwealth University

2000-present              MII, Course Faculty, Neurology Course, Virginia Commonwealth University

              2001-2006              MI, Course Faculty, Neuroanatomy, Virginia Commonwealth                                                         University

 

12.              Bibliography

 

12.1         Papers Published

 

Morton, L. In Memoriam: John M. “Jack” Pellock, MD (1943 to 2016). Pediatric Neurology, 64, 35

                           

Hussain A, Seinfeld S, Morton L. Genetic Association with Ictal Cardiorespiratory Phenomena: SCN8A Case Series. J Pediatr Neurol. 2016; 14(04):151-155

 

Gowda SN, Morton LD, Borad SJ et al. “Elevation of Cardiac Troponins in Prolonged Status Epilepticus: A Retrospective Chart Analysis” SOJ Neurology, 2013

 

Jain, SV,  Simakajornboon S, Shapiro SM, Morton LD, Leszczyszyn DJ, Simakajornboon N: “Obstructive sleep apnea in children with epilepsy: prospective pilot trial”, Acta Neurologica Scandinavica 2012, 125(1) e3-6.

 

Seinfeld S, Morton LD, Tye G: “Epilepsy surgery in a patient with Dandy-Walker variant”, Journal of Pediatric Epilepsy 2012 1(2:125-8.).

.

 

Jain, SV, Morton LD:  “Ischemic Stroke and Excellent Recovery After Administration of Intravenous Tissue Plasminogen Activator”, Pediatric Neurology 2008, 38(2):  126-129.

 

Morton LD, O’Hara KA, Coots BP, Pellock JM: Safety of Rapid Intravenous Valproate Infusion in Pediatric Patients, Pediatric Neurology 2007, 36(2): 81-83.

 

              Riviello JJ Jr, Ashwal S, Hirtz D, Glauser T, Ballaban-Gil K, Kelley K, Morton LD, Phillips S, Sloan E, Shinnar S; American Academy of Neurology Subcommittee; Practice Committee of the Child Neurology Society. Practice parameter: diagnostic assessment of the child with status epilepticus (an evidence-based review): report of the Quality

Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.  Neurology. 2006 Nov 14; 67(9):1542-50. Review.

Wheless, JW, Vazquez BR, Kanner AM, Ramsay RE, Morton L, Pellock JM:  Rapid infusion with valproate sodium is well tolerated in patients with epilepsy, Neurology, 2004 Oct 26;63(8):1507-8.

 

Donofrio MT, Bremer YA, Schieken RM, Gennings C, Morton LD, Eidem BW, Cetta F, Falkensammer CB, Huhta JC, Kleinman CS:  “Autoregulation of cerebral blood flow in fetuses with congenital heart disease:  the brain sparing effect”:  Pediatric Cardiology, 2003 Sep-Oct; 24(5):436-43.

 

Towne AR, Garnett LK, Waterhouse EJ, Morton LD, DeLorenzo RJ:  “The use of topiramate in refractory status epilepticus”:  Neurology, 2003 Jan 28;60(2):332-4.

 

Alehan FK, Morton LD, Pellock JM: Utility of electroencephalography in the pediatrics emergency department, Journal of Child Neurology, 2001 16; 484-7.

 

Morton LD: Evaluation of seizure disorders in the pediatric patient.  Advanced Studies in Medicine, 2001; Vol 1(4):141-6.

 

Kerrigan JF, Shields WD, Nelson TY, Bluestone DL, Dodson WE, Bourgeois BF, Pellock JM, Morton LD, Monaghan EP:  Ganaxolone for treating intractable infantile spasms:  a multicenter, open-label, add-on trial.  Epilepsy Res, 2000 Dec;42(2-3):133-9.

 

Pellock JM, Morton LD: Treatment of epilepsy in the multiply handicapped.  Mental Retardation and Developmental Disabilities Research Reviews, 2000; 6:309-23.

 

Morton LD, Pellock JM: Overview of childhood epilepsy and epileptic syndromes and advances in therapy.  Current Pharmaceutical Design, 2000; 6:879-900.

 

Morton LD: Treatment of status epilepticus with intravenous valproate.  Clinical Lessons in Epilepsy 2000; 3(1):12-14.

 

DeLorenzo RJ, Garnett LK, Towne AR, Waterhouse EJ, Boggs JG, Morton LD, Choudhry MA, Barnes T, Ko D.  Comparison of status epilepticus with prolonged seizure episodes lasting from 10 to 29 minutes.  Epilepsia, 1999;40(2):164-169.

 

Alehan FK, Morton LD, Pellock JM.  Treatment of absence status with intravenous valproate. Neurology, 1999 Mar 10; 52(4):889-90.

 

Waterhouse EJ, Garnett LK, Towne AR, Morton LD, Barnes T, Ko D, DeLorenzo RJ: Prospective population-based study of intermittent and continuous convulsive status epilepticus. Epilepsia, 1999;40(6):752-8.

 

Boggs JG, Marmarou A, Agnew JP, Morton LD, et al: Hemodynamic monitoring prior to and at the time of death in status epilepticus. Epilepsy Research 1998, 31(3):199-209.

 

Gibbs III John W, Morton LD, Amaker B, Ward JD, Holloway KL, Coulter DA: Physiological analysis of Rasmussen’s encephalitis: patch clamp recordings of altered inhibitory neurotransmitter function in resected frontal cortical tissue.  Epilepsy Research 1998, 31(1):13-27.

 

Morton LD, Rizkallah E, Pellock JM:  New drug therapy for acute seizure management.  Seminars in Pediatric Neurology 1997, Mar 4(1):51-63.

 

Bannister SM, Morton LD, Pellock JM: New antiepileptic drugs: case studies.  Seminars in Pediatric Neurology 1997, Mar 4(1):64-67.

 

Morton LD, Pellock JM: Diagnosis and treatment of epilepsy in children and adolescents (review). Drugs 1996; 51(3):399-414.

 

VonScheven E, Arthreya BH, Rose CD, Morton LD: Clinical characteristics of antiphospholipid antibody syndrome.  Journal of Pediatrics 1996;129(3):339-345.

 

Tam DA, Morton LD, Leshner RT: Leukopenia in a patient receiving intravenous gamma globulin.  Journal of Neuroimmunology 1996; 64:175-8.

 

12.2              Abstracts

 

 

 

Way E, Morton LD. Extreme Delta Brush Pattern in Hashimotos Encephalitis: A Case Report. December 2018. American Epilepsy Society Meeting. New Orleans, LA.

 

Vu TH, Ono K, Gonzalez Montoya V, Gowda SN, Morton LD. EEG Findings in Pediatric Patients With Anti-MDA Encephalitis December 2015.American Epilepsy Society Meeting. Philadelphia, PA.

 

Ozbalik M, Gowda SN, Morton LD.Limitations of Quantative EEG analysis in the adult ICU.”  April 2014. American Academy of Neurology. Philadelphia, PA. Platform Presentation.

 

Gowda SN,  Gonzalez-Montoya VH, Kernitsky L, Morton LD. Prognostic Implications of Electroencephalogram [EEG] Patterns in Post Anoxic Hypothermic Patients. December 2012. American Epilepsy Society Annual Meeting. San Diego, CA.

 

Borad SJ, Gowda SN, Morton LD, Vota SA, Towne AR, Voils SA,. Carrico RJ, Thacker LR, .Delorenzo RJ. Status Epilepticus (SE) and an Associated Increase in Mortality in Patients with Coronary Artery Disease (CAD). May 2012. American Academy of Neurology. New Orleans, LA.

 

Wong J, Gowda SN, Vota SA, Morton LD, DeLorenzo RJ, Towne AR. Utilization and Effectiveness of Different Antiepileptic Drugs in Status Epilepticus. May 2012. American Academy of Neurology. New Orleans, LA.

 

Gowda SN, Borad SJ, Morton LD, L. Kernitsky, S. A. Vota, A. R. Towne, R. Delorenzo. Significance of elevated troponins in patients with status epilepticus. December 2011, American Epilepsy Society, Baltimore, MD. Poster Presentation.  

 

Morton LD, Kopec L, Ramakrishnan V, Towne A, Waterhouse EJ, Kernitsky L, DeLorenzo RJ.  Utility of Imaging in Status Epilepticus. December 2010, American Epilepsy Society, San Antonio, TX. Poster Presentation.

 

Kopec L., Masho S, Waterhouse EJ, Morton LD, Byers SF, DeLorenzo RJ, Towne
AR.  Outcomes of Status Epilepticus in the Elderly.  December 2007, American Epilepsy Society, Philadelphia, PA.  Poster Presentation.

 

Kernitsky L, Morton LD.  Ambulatory EEG:  is it a valuable tool in the investigation of possible epileptic events.  December 2006, American Epilepsy Society, San Diego, CA.  Poster presentation.

 

Morton LD, Julius AD, O’Hara K, Jakkampudi V, Corrie S:  Comparison of non-epileptic events to patient history in pediatric admissions to epilepsy monitoring units:  May 2006, American Academy of Neurology, San Diego, CA:  Poster presentation.

 

Morton LD, Jakkampudi VV, Kernitsky L, Towne AR, Corrie WS:  “Safety of acute antiseizure medication withdrawal for phase I monitoring in an epilepsy monitoring unit”:  December 2005, American Epilepsy Society, Washington, DC:  Poster Presentation.

 

Garnett LK, Waterhouse E, Morton LD, Towne AR, Byers S, Bieber J, Ramakrishnan V, Zhao J, DeLorenzo R:  “Singe versus multiple episodes of status epilepticus during a hospital admission”:  December 2005, American Epilepsy Society, Washington, DC:  Poster Presentation.

 

Waterhouse EJ, Garnett LK, Ramakrishnan V, Morton LD, Towne AR, DeLorenzo RJ:  “Improved survival in status epilepticus patients with history of seizure”:  December 2005, American Epilepsy Society, Washington DC:  Poster Presentation.

 

Morton LD, O’Hara KA, Pellock JM:  “Tiagabine as initial treatment for infantile spasms:  a pilot study”:  December 2004, American Epilepsy Society, New Orleans, LA:  Poster Presentation.

 

Cors CS, Ramakrishnan V, DeLorenzo RJ, Towne AR, Garnett LK, Waterhouse EJ, Kernitsky L, Morton LD, Penburthy LT: Analyzing status epilepticus data with multiple etiologies, Epilepsia 2004, 45 (Suppl. 7):257.

 

Garnett LK, Towne AR, Ramakrishnan V, Waterhouse EJ, Byers SF, Bieber JM, Morton LD, Kernitsky L, DeLorenzo RJ:  Elevated BUN predicts status epilepticus mortality, Epilepsia 2004, 45(Suppl. 7):281.

 

Waterhouse EJ, Garnett LK, Ramakrishnan V, Towne AR, Morton LD, DeLorenzo RJ:  Acidosis and status epilepticus:  associations and effects, Epilepsia 2004, 45(Suppl. 7):105.

 

Waterhouse EJ, Garnett LK, Ramakrishnan V, Towne AR, Morton LD, DeLorenzo RJ:  “Acidosis and status epilepticus:  associates and effects”:  December 2004, American Epilepsy Society, New Orleans, LA:  Poster Presentation.

 

Kazi AK, Morton LD, Pellock JM, O’Hara KA, Sutherland LN, Ramakrishnan V:  “Early versus late vagus nerve stimulation therapy in pediatric epilepsy”:  December 2004, American Epilepsy Society, New Orleans, LA:  Poster Presentation.

 

Cors CS, Ramakrishnan V, DeLorenzo RJ, Towne AR, Garnett LK, Waterhouse, EJ, Kernitsky L, Morton LD, Penberthy LT:  “Analyzing status epilepticus data with multiple etiologies”:  December 2004, American Epilepsy Society, New Orleans, LA:  Poster Presentation.

 

Garnett LK, Towne AR, Ramakrishnan V, Waterhouse EJ, Byers SF, Bieber JM, Morton LD, Kernitsky L, DeLorenzo RJ:  “Elevated BUN  predicts status epilepticus mortality”:  December 2004, American Epilepsy Society, New Orleans, LA:  Poster Presentation.

 

Garnett LK, DeLorenzo RJ, Morton LD, Waterhouse EJ, Byers SF, Bieber JM, Cors CS, Towne AR:  “Status epilepticus:  locations and outcomes”:  December 2003, American Epilepsy Society, Boston, MA:  Poster Presentation.

 

Waterhouse EJ, Garnett LK, DeLorenzo RJ, Morton LD, Cors CS, Towne AR:  “Status epilepticus in African Americans”:  December 2003, American Epilepsy Society, Boston, MA:  Poster Presentation.

 

Morton LD, O’Hara KA, Dyer A, Patel KJ, Byers SF, Garnett WR:  “The safety and efficacy of intravenous valproate (Depacon) in the treatment of seizures in adult patients”:  December 2003, American Epilepsy Society, Boston, MA:  Poster Presentation.

 

O’Hara KA, Morton LD:  “Pediatric experience in encephalopathic epilepsies with the vagus nerve stimulator”:  December 2003, American Epilepsy Society, Boston, MA:  Poster Presentation.

 

 

O’Hara KA, Morton LD, Garnett WF, Pellock JM:  “Extremely high dose requirements of intravenous valproic acid in two pediatric patients with status epilepticus”: December 2002, American Epilepsy Society, Seattle, WA; Poster Presentation.

 

Kernitsky L, Morton LD, O’Hara KA, Pellock JM, DeLorenzo RJ, Garnett LK, Campbell E, Bucco A, Towne AR:  “Refractory status epilepticus in children”; December 2002, American Epilepsy Society, Seattle, WA; Poster Presentation.

 

Towne AR, Garnett LK, Waterhouse EJ, Morton LD, Campbell ED, DeLorenzo RJ:  “Status epilepticus in the elderly population”: December 2002, American Epilepsy Society, Seattle WA: Platform Presentation.

 

Waterhouse EJ, Garnett LK, Morton LD, Campbell E, DeLorenzo RJ, Towne AR:  “New onset status epilepticus in hospitalized patients – a distinct subset of status patients”: December 2002, American Epilepsy Society, Seattle WA:  Poster Presentation.

 

Garnett LK, Morton LD, Waterhouse EJ, Kernitsky L, Campbell ED, DeLorenzo RJ, Towne AR: Bouncing back after status epilepticus- factors affecting functional outcome”: December 2002, American Epilepsy Society, Seattle WA:  Poster Presentation.

 

Morton LD, Youssef AF, Lloyd E, Kiorpes AL, Goldsworthy TL, Fort FL:  “Evaluation of carcinogenic response in the eker rat following short-term exposure to selected nephrotoxins and carcinogens”: Toxicology Pathology, 2002 Sep-Oct;30(5):559-64.

 

Morton LD, Towne AR, Garnett LK, Byers SF, Brown AJ, Waterhouse EJ, Pellock JM, DeLorenzo RJ: “Mortality of status epilepticus in the first year of life”, December 2001, American Epilepsy Society, Philadelphia, PA; Poster Presentation.

 

Morton LD, Towne AR, Garnett LK, Brown AJ, Waterhouse EJ: “Intravenous valproate in an intensive care setting for the treatment of status epilepticus (SE)”: May 2001, American Academy of Neurology, Philadelphia, PA; Poster Presentation.

 

Morton LD, Towne AR, Garnett LK, Byers SF, Brown AJ, O’Hara KA, Waterhouse EJ, Pellock JM, DeLorenzo EJ: “Safety and efficacy of intravenous valproate in status epilepticus”, December 2000, American Epilepsy Society, Los Angeles, CA: Platform Presentation.

 

O’Hara KA, Morton LD, Meloche NM, Hickman RW, Pellock JM: “Intravenous valproate experience in pediatric patients less than 32 months of age”, December 2000, American Epilepsy Society, Los Angeles, CA; Platform Presentation.

 

Garnett LK, Towne AR, Morton LD, Waterhouse EJ, Brown AJ, DeLorenzo RJ: “Status epilepticus and concomitant cardiovascular disease”, December 2000, American Epilepsy Society, Los Angeles, CA; Poster Session.

 

Meloche NM, O’Hara KA, Morton LD: “Changes in sleep quality in children and adults with the vagus nerve stimulator”, December 2000, American Epilepsy Society, Los Angeles, CA; Poster Session.

 

Morton LD, Leszczyszyn DJ, Kopec Garnett L, Towne AR, Waterhouse EJ, Pellock JM, DeLorenzo RJ: “Maturational changes in the EEG of status epilepticus in the first six months of life”, May 2000, American Academy of Neurology, San Diego, CA; Platform Presentation.

 

Morton LD, O’Hara KA, Meloche NM, Garnett WR, Pellock JM: “Fosphenytoin experience in pediatric patients”, December 1999, American Epilepsy Society, Orlando, FL; Poster Presentation.

 

Meloche NM, Vorenberg AJ, Morton LD, O’Hara KA, Driscoll-Bannister SM, Pellock JM: “Anti-epileptic drug levels in the pediatric emergency department for patients presenting with breakthrough seizures”, December 1999, American Epilepsy Society, Orlando, FL; Poster Session.

 

Towne AR, Garnett LK, Waterhouse EJ, Morton LD, Brown AJ, Ko D, DeLorenzo RJ: “Risk factors for refractory status epilepticus”, December 1999, American Epilepsy Society, Orlando, FL; Poster Session.

 

Garnett LK, Towne AR, Waterhouse EJ, Morton LD, Brown AJ, Barnes TY, DeLorenzo RJ: “Clinical study of prolonged seizures lasting 10 to 29 minutes”, December 1999, American Epilepsy Society, Orlando, FL; Poster Session.

 

Alehan FK, Morton LD, Pellock JM: “Electroencephalogram in the pediatric emergency department: is it useful? April 1999, American Academy of Neurology, Toronto, Canada; Poster Session.

 

Watemberg N, Alehan FP, Pavot P, Morton LD, Towne AR: “Clinical and laboratory correlates of frontal intermittent rhythmic delta activity (FIRDA)”, April 1999, American Academy of Neurology, Toronto, Canada; Poster Session.

 

Waterhouse EJ, Garnett LK, Towne AR, Morton LD, Barnes T, Ko D, DeLorenzo RJ: “Risk of repeat episodes of status epilepticus”, April 1999, American Academy of Neurology, Toronto, Canada; Platform Presentation.

 

Morton LD, Watemberg NM, Driscoll-Bannister S, O’Hara KA, Garnett LK, Pellock JM, DeLorenzo RJ: “Long-term outcome in status epilepticus in the first year of life”, December 1998, American Epilepsy Society, San Diego, CA; Platform Presentation.

 

Knapp LE, Morton LD, Pellock JM, Mitchell WG, Wheless JW, Burger PJ, Henkin SA, Smith MF, Kugler AR: “Fosphenytoin safety and pharmacokinetics in pediatric patients”, December 1998, American Epilepsy Society, San Diego, CA; Platform Presentation.

 

Morton LD: Clinical experience with fosphenytoin in children.  Journal of Child Neurology 1998 Oct; 13 (Suppl 1): S19-22.

 

Waterhouse EJ, Kopec Garnett L, Towne AR, Morton LD, Daijin K, DeLorenzo RJ: Convulsive status epilepticus duration, rather than ictal time, predicts mortality. Epilepsia 1998, 39 (Suppl 6), 7.052.

 

Towne AR, Waterhouse EJ, Morton LD, Kopec Garnett L, Brown AJ, DeLorenzo RJ: Unrecognized nonconvulsive status epilepticus in comatose patients.  Epilepsia 1998, 39 (Suppl 6), K 07.


Kopec Garnett L, Towne AR, Waterhouse EJ, Morton LD, Brown Al, Barnes TY,

 

DeLorenzo RJ: Low mortality in patient with prolonged seizure episodes lasting from 10 to 29 minutes.  Epilepsia 1998, 39 (Suppl 6), 7.051.

 

Morton LD, DeLorenzo C, Garnett LK, Pellock JM, DeLorenzo RJ: “Morbidity and mortality of status epilepticus in the first year of life”, May 1998, American Academy of Neurology, Minneapolis, MN; Platform Presentation.

 

Towne AR, Boggs JG, Waterhouse EJ, Garnett LK, Morton LD, DeLorenzo RJ: Natural history of untreated status epilepticus.  Epilepsia, 1997, 38 (Suppl 8), J06.

 

DeLorenzo RJ, Ko D, Towne AR, Kopec Garnett LK, Boggs JG, Waterhouse EJ, Morton LD: Prediction of outcome of status epilepticus, Epilepsia 1997, 38 (Suppl 8), J 07.

 

Morton LD, Pellock JM, Maria BL, Legarda S, Gilman JT, Smith MF, Knapp LL, Kugler AR: “Fosphenytoin safety and pharmacokinetics in children”, December 1997, American Epilepsy Society, Boston, MA.

 

Morton LD, Pellock JM, Gilman JT, Maria BL, Smith MF, Kugler AR: “Fosphenytoin pharmacokinetics and safety in children, October 1997, Child Neurology Society, Phoenix, AZ.

 

Morton LD, Gutcher G, Pellock JM, DeLorenzo RJ: “Population based incidence of neonatal status epilepticus in Richmond, Virginia”, April 1997, American Academy of Neurology, Boston, MA.

 

Boggs JG, Marmarou A, Agnew JT, Morton LD, Towne AR, Waterhouse EJ, Pellock JM, DeLorenzo RJ: “Hemodynamic monitoring prior to death in status epilepticus”, April 1997, American Academy of Neurology, Boston, MA.

 

Morton LD, Pellock JM, Legarda S, Besserer J, Garofalo EA, Knapp LE, Kugler AR, Smith MF: “Fosphenytoin pharmacokinetics and safety in pediatric patients”, December 1996, American Epilepsy Society, San Francisco, CA.

 

Garnett LK, Towne AR, Calabrese TD, Jester AJ, Brown JG, Boggs JG, Waterhouse EJ, Morton LD, DeLorenzo RJ: “Assessment of status epilepticus: the continuous quality improvement process as an educational tool in a teaching hospital”, December 1996, American Epilepsy Society, San Francisco, CA.

 

Morton LD, Brooks-Kayal A, Clancy RR, Brown L: “SPECT findings in four pediatric patients with acquired aphasic and epileptiform EEG”, May 1995, American Academy of Neurology, Seattle, WA.

 

Morton LD, Legido AL: “Neurological outcome in pediatric liver transplant patients”, American Pediatric Research Conference, 1987.

 

12.3              Books/Chapters             

 

Morton LD: "Autoimmune and Selected Disorders Associated With Epilepsy”. In: Pellock’s Pediatric Epilepsy Diagnosis and Therapy Fourth Edition. Demos Medical Publishing, 2016

 

Mathew DK, Morton LD: "Evaluating the Child With Seizure". In: Pellock’s Pediatric Epilepsy Diagnosis and Therapy Fourth Edition. Demos Medical Publishing, 2016

 

Morton LD, Pellock JM: “Status Epilepticus”. In: Pediatric Neurology, Principles and Practice, 5th Edition. Mosby Elsevier, 2012.

 

Morton LD: “Selected Disorders Associated with Epilepsy”.  In: Pediatric Epilepsy Diagnosis and Therapy, 3rd Edition.  Demos Medical Publishing, 2008

 

Morton LD, Pellock JM: “Status Epilepticus”. In: Pediatric Neurology, Principles and Practice, 4th Edition. Mosby Elsevier, 2006.

 

Morton LD: “Headaches”, “Dizziness”, and “Vertigo”.  In: Neurology Section of Children’s Hospital of Philadelphia Handbook of Pediatrics, 3rd Edition, Lippincott Williams & Wilkins, 2003.

 

Myer EC, Morton LD: “Selected Disorders Associated with Epilepsy”.  In: Pediatric Epilepsy Diagnosis and Therapy, 2nd Edition.  Demos Medical Publishing, 2001.

 

Morton LD: “Headaches”, “Dizziness”, and “Vertigo”.  In: Neurology Section of Children’s Hospital of Philadelphia Handbook of Pediatrics.  WB Saunders, 1996.

 

Morton LD, Myer EC: Absence Seizures.  In: Johnson RT and Griffin JW (eds): Current Therapy in Neurologic Disease.  Fifth Edition, Philadelphia, PA: Mosby Year Book, 1996.

 

12.4         Other

 

Watemberg NM, Morton LD: Images in Clinical Medicine, “Periodic Lateralized Epileptiform Discharges”.  NEJM 1996; 334(10): 634.

 

 

 

Revised February, 2018